Results 201 to 210 of about 281,775 (299)
Abstract Background and aims The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.
Qinghong Li +12 more
wiley +1 more source
ALPK1 agonists: a new strategy for cancer immunotherapy. [PDF]
Lim MCC, Maubach G, Naumann M.
europepmc +1 more source
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher +12 more
wiley +1 more source
Advances in lanthanide probes for selective anion recognition and sensing in water. [PDF]
Siu C, Butler SJ.
europepmc +1 more source
An ART-fold Rhs toxin from Pluralibacter gergoviae defines Tne5, a novel family of NAD(P) glycohydrolases effectors. [PDF]
Desjardins JB +3 more
europepmc +1 more source
Acceptorless Dehydrogenative Polymerization. [PDF]
Liu X, Lathrop JL, Miyake GM.
europepmc +1 more source
Research progress on the role of inflammatory mediators in the pathogenesis of epilepsy
In the central nervous system, activated immune cells lead to the overproduction of inflammatory mediators through the corresponding signal pathway. Under the stimulation of inflammatory factors, neuroinflammation ultimately occurs. Overexpression of inflammatory mediators and activated immunocytes plays an important role in the emergence and ...
Yue Yu, Fei‐Ji Sun
wiley +1 more source
Nutrition Information Briefs - Niacin. [PDF]
Meyer-Ficca ML, Chini CC.
europepmc +1 more source
The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source

